The DOI matches its Crossref record; 203 of the 203 references it cites were found in a registry or an index.
Immunological landscape and immunotherapy of hepatocellular carcinoma
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Coussens, L. M., & Werb, Z. (2002) · Nature · doi:10.1038/nature01322 · Cited by 15,111
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
Galle, P. R., Forner, A., Llovet, J. M., Mazzaferro, V., Piscaglia, F., Raoul, J.-L., Schirmacher, P., & Vilgrain, V. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.03.019 · Cited by 11,406
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Vogelstein, B., Papadopoulos, N., Velculescu, V. E., Zhou, S., Diaz, L. A., & Kinzler, K. W. (2013) · Science · doi:10.1126/science.1235122 · Cited by 7,863
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609
Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N., Balmanoukian, A. S., Eder, J. P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501824 · Cited by 6,198
Cancer immunoediting: from immunosurveillance to tumor escape
Dunn, G. P., Bruce, A. T., Ikeda, H., Old, L. J., & Schreiber, R. D. (2002) · Nature Immunology · doi:10.1038/ni1102-991 · Cited by 5,393
Freeman, G. J., Long, A. J., Iwai, Y., Bourque, K., Chernova, T., Nishimura, H., Fitz, L. J., Malenkovich, N., Okazaki, T., Byrne, M. C., et al. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.7.1027 · Cited by 5,294
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Herbst, R. S., Soria, J.-C., Kowanetz, M., Fine, G. D., Hamid, O., Gordon, M. S., Sosman, J. A., McDermott, D. F., Powderly, J. D., Gettinger, S. N., et al. (2014) · Nature · doi:10.1038/nature14011 · Cited by 5,231
EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma
European Association for the Study of the Liver, & European Organisation for Research and Treatment of Cancer (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2011.12.001 · Cited by 5,218
Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
Snyder, A., Makarov, V., Merghoub, T., Yuan, J., Zaretsky, J. M., Desrichard, A., Walsh, L. A., Postow, M. A., Wong, P., Ho, T. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1406498 · Cited by 4,286
Nivolumab plus Ipilimumab in Advanced Melanoma
Wolchok, J. D., Kluger, H., Callahan, M. K., Postow, M. A., Rizvi, N. A., Lesokhin, A. M., Segal, N. H., Ariyan, C. E., Gordon, R.-A., Reed, K., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1302369 · Cited by 4,230
Restoring function in exhausted CD8 T cells during chronic viral infection
Barber, D. L., Wherry, E. J., Masopust, D., Zhu, B., Allison, J. P., Sharpe, A. H., Freeman, G. J., & Ahmed, R. (2006) · Nature · doi:10.1038/nature04444 · Cited by 3,986
Functional Polarization of Tumour-Associated Macrophages by Tumour-Derived Lactic Acid
Colegio, O. R., Chu, N.-Q., Szabo, A. L., Chu, T., Rhebergen, A. M., Jairam, V., Cyrus, N., Brokowski, C. E., Eisenbarth, S. C., Phillips, G. M., et al. (2014) · Nature · doi:10.1038/nature13490 · Cited by 3,046
Llovet, J. M., & Bruix, J. (2003) · Hepatology · doi:10.1053/jhep.2003.50047 · Cited by 3,029
Activation of NK Cells and T Cells by NKG2D, a Receptor for Stress-Inducible MICA
Bauer, S., Groh, V., Wu, J., Steinle, A., Phillips, J. H., Lanier, L. L., & Spies, T. (1999) · Science · doi:10.1126/science.285.5428.727 · Cited by 2,999
PD-L2 is a second ligand for PD-1 and inhibits T cell activation
Latchman, Y., Wood, C. R., Chernova, T., Chaudhary, D., Borde, M., Chernova, I., Iwai, Y., Long, A. J., Brown, J. A., Nunes, R., et al. (2001) · Nature Immunology · doi:10.1038/85330 · Cited by 2,955
Regulatory T cells: mechanisms of differentiation and function
Josefowicz, S. Z., Lu, L.-F., & Rudensky, A. Y. (2012) · Annual Review of Immunology · doi:10.1146/annurev.immunol.25.022106.141623 · Cited by 2,866
Nivolumab and ipilimumab versus ipilimumab in untreated melanoma
Postow, M. A., Chesney, J., Pavlick, A. C., Robert, C., Grossmann, K., McDermott, D., Linette, G. P., Meyer, N., Giguere, J. K., Agarwala, S. S., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1414428 · Cited by 2,781
Lymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4
Waterhouse, P., Penninger, J. M., Timms, E., Wakeham, A., Shahinian, A., Lee, K. P., Thompson, C. B., Griesser, H., & Mak, T. W. (1995) · Science · doi:10.1126/science.270.5238.985 · Cited by 2,766
Morgan, R. A., Yang, J. C., Kitano, M., Dudley, M. E., Laurencot, C. M., & Rosenberg, S. A. (2010) · Molecular Therapy · doi:10.1038/mt.2010.24 · Cited by 2,533
Deaglio, S., Dwyer, K. M., Gao, W., Friedman, D., Usheva, A., Erat, A., Chen, J.-F., Enjyoji, K., Linden, J., Oukka, M., et al. (2007) · The Journal of Experimental Medicine · doi:10.1084/jem.20062512 · Cited by 2,470
Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer
Twyman-Saint Victor, C., Rech, A. J., Maity, A., Rengan, R., Pauken, K. E., Stelekati, E., Benci, J. L., Xu, B., Dada, H., Odorizzi, P. M., et al. (2015) · Nature · doi:10.1038/nature14292 · Cited by 2,434
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
Powles, T., Eder, J. P., Fine, G. D., Braiteh, F. S., Loriot, Y., Cruz, C., Bellmunt, J., Burris, H. A., Petrylak, D. P., Teng, S.-L., et al. (2014) · Nature · doi:10.1038/nature13904 · Cited by 2,381
CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation.
Krummel, M. F., & Allison, J. P. (1995) · The Journal of experimental medicine · doi:10.1084/jem.182.2.459 · Cited by 2,245
Noman, M. Z., Desantis, G., Janji, B., Hasmim, M., Karray, S., Dessen, P., Bronte, V., & Chouaib, S. (2014) · Journal of Experimental Medicine · doi:10.1084/jem.20131916 · Cited by 2,166
Molecular Signature of CD8+ T Cell Exhaustion during Chronic Viral Infection
Wherry, E. J., Ha, S.-J., Kaech, S. M., Haining, W. N., Sarkar, S., Kalia, V., Subramaniam, S., Blattman, J. N., Barber, D. L., & Ahmed, R. (2007) · Immunity · doi:10.1016/j.immuni.2007.09.006 · Cited by 2,103
PD-L1 regulates the development, maintenance, and function of induced regulatory T cells
Francisco, L. M., Salinas, V. H., Brown, K. E., Vanguri, V. K., Freeman, G. J., Kuchroo, V. K., & Sharpe, A. H. (2009) · Journal of Experimental Medicine · doi:10.1084/jem.20090847 · Cited by 2,079
The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity
Zhu, C., Anderson, A. C., Schubart, A., Xiong, H., Imitola, J., Khoury, S. J., Zheng, X. X., Strom, T. B., & Kuchroo, V. K. (2005) · Nature Immunology · doi:10.1038/ni1271 · Cited by 2,057
Cancer Immunotherapy Based on Mutation-Specific CD4+ T Cells in a Patient with Epithelial Cancer
Tran, E., Turcotte, S., Gros, A., Robbins, P. F., Lu, Y.-C., Dudley, M. E., Wunderlich, J. R., Somerville, R. P., Hogan, K., Hinrichs, C. S., et al. (2014) · Science · doi:10.1126/science.1251102 · Cited by 1,718
Woo, S.-R., Turnis, M. E., Goldberg, M. V., Bankoti, J., Selby, M., Nirschl, C. J., Bettini, M. L., Gravano, D. M., Vogel, P., Liu, C. L., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-1620 · Cited by 1,647
Robbins, P. F., Morgan, R. A., Feldman, S. A., Yang, J. C., Sherry, R. M., Dudley, M. E., Wunderlich, J. R., Nahvi, A. V., Helman, L. J., Mackall, C. L., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.2537 · Cited by 1,632
Inhibitory B7-family molecules in the tumour microenvironment
Zou, W., & Chen, L. (2008) · Nature Reviews Immunology · doi:10.1038/nri2326 · Cited by 1,608
An Interaction between Kynurenine and the Aryl Hydrocarbon Receptor Can Generate Regulatory T Cells
Mezrich, J. D., Fechner, J. H., Zhang, X., Johnson, B. P., Burlingham, W. J., & Bradfield, C. A. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0903670 · Cited by 1,601
Llovet, J. M., Ducreux, M. P., Lencioni, R. A., Bisceglie, A. M. D., Dufour, J., Greten, T. F., Raymond, É., Roskams, T., Mazzaferro, V., Bruix, J., et al. (2012) · Cited by 1,488
Monney, L., Sabatos, C. A., Gaglia, J. L., Ryu, A., Waldner, H., Chernova, T., Manning, S., Greenfield, E. A., Coyle, A. J., Sobel, R. A., et al. (2002) · Nature · doi:10.1038/415536a · Cited by 1,472
Mittal, D., Gubin, M. M., Schreiber, R. D., & Smyth, M. J. (2014) · Current Opinion in Immunology · doi:10.1016/j.coi.2014.01.004 · Cited by 1,471
Galectins as modulators of tumour progression
Liu, F.-T., & Rabinovich, G. A. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1527 · Cited by 1,439
Johnson, L. A., Morgan, R. A., Dudley, M. E., Cassard, L., Yang, J. C., Hughes, M. S., Kammula, U. S., Royal, R. E., Sherry, R. M., Wunderlich, J. R., et al. (2009) · Blood · doi:10.1182/blood-2009-03-211714 · Cited by 1,418
Molecular Signature of CD8+ T Cell Exhaustion during Chronic Viral Infection
Wherry, E. J., Ha, S.-J., Kaech, S. M., Haining, W. N., Sarkar, S., Kalia, V., Subramaniam, S., Blattman, J. N., Barber, D. L., & Ahmed, R. (2007) · Immunity · doi:10.1016/j.immuni.2007.11.006 · Cited by 1,354
A Special Population of Regulatory T Cells Potentiates Muscle Repair
Burzyn, D., Kuswanto, W., Kolodin, D., Shadrach, J. L., Cerletti, M., Jang, Y., Sefik, E., Tan, T. G., Wagers, A. J., Benoist, C., et al. (2013) · Cell · doi:10.1016/j.cell.2013.10.054 · Cited by 1,234
Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing
Yadav, M., Jhunjhunwala, S., Phung, Q. T., Lupardus, P., Tanguay, J., Bumbaca, S., Franci, C., Cheung, T. K., Fritsche, J., Weinschenk, T., et al. (2014) · Nature · doi:10.1038/nature14001 · Cited by 1,186
VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors
Voron, T., Colussi, O., Marcheteau, E., Pernot, S., Nizard, M., Pointet, A.-L., Latreche, S., Bergaya, S., Benhamouda, N., Tanchot, C., et al. (2015) · Journal of Experimental Medicine · doi:10.1084/jem.20140559 · Cited by 1,179
Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer
Nagaraj, S., Gupta, K., Pisarev, V., Kinarsky, L., Sherman, S., Kang, L., Herber, D. L., Schneck, J., & Gabrilovich, D. I. (2007) · Nature Medicine · doi:10.1038/nm1609 · Cited by 1,174
PD-1 identifies the patient-specific CD8+ tumor-reactive repertoire infiltrating human tumors
Gros, A., Robbins, P. F., Yao, X., Li, Y. F., Turcotte, S., Tran, E., Wunderlich, J. R., Mixon, A., Farid, S., Dudley, M. E., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci73639 · Cited by 1,111
Macrophages Regulate the Angiogenic Switch in a Mouse Model of Breast Cancer
Lin, E. Y., Li, J.-F., Gnatovskiy, L., Deng, Y., Zhu, L., Grzesik, D. A., Qian, H., Xue, X.-N., & Pollard, J. W. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1278 · Cited by 1,074
Natural selection of tumor variants in the generation of “tumor escape” phenotypes
Khong, H. T., & Restifo, N. P. (2002) · Nature Immunology · doi:10.1038/ni1102-999 · Cited by 1,058
Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors
Motz, G. T., Santoro, S. P., Wang, L.-P., Garrabrant, T., Lastra, R. R., Hagemann, I. S., Lal, P., Feldman, M. D., Benencia, F., & Coukos, G. (2014) · Nature Medicine · doi:10.1038/nm.3541 · Cited by 1,035
Jongbloed, S. L., Kassianos, A. J., McDonald, K. J., Clark, G. J., Ju, X., Angel, C. E., Chen, C.-J. J., Dunbar, P. R., Wadley, R. B., Jeet, V., et al. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20092140 · Cited by 1,027
Parkhurst, M. R., Yang, J. C., Langan, R. C., Dudley, M. E., Nathan, D.-A. N., Feldman, S. A., Davis, J. L., Morgan, R. A., Merino, M. J., Sherry, R. M., et al. (2011) · Molecular Therapy · doi:10.1038/mt.2010.272 · Cited by 1,020
Sangro, B., Gomez-Martin, C., de la Mata, M., Iñarrairaegui, M., Garralda, E., Barrera, P., Riezu-Boj, J. I., Larrea, E., Alfaro, C., Sarobe, P., et al. (2013) · Journal of Hepatology · doi:10.1016/j.jhep.2013.02.022 · Cited by 980
Self-citationPeggs, K. S., Quezada, S. A., Chambers, C. A., Korman, A. J., & Allison, J. P. (2009) · Journal of Experimental Medicine · doi:10.1084/jem.20082492 · Cited by 967
LAG-3, a novel lymphocyte activation gene closely related to CD4.
Triebel, F., Jitsukawa, S., Baixeras, E., Roman-Roman, S., Genevee, C., Viegas-Pequignot, E., & Hercend, T. (1990) · The Journal of experimental medicine · doi:10.1084/jem.171.5.1393 · Cited by 925
Matsuzaki, J., Gnjatic, S., Mhawech-Fauceglia, P., Beck, A., Miller, A., Tsuji, T., Eppolito, C., Qian, F., Lele, S., Shrikant, P., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1003345107 · Cited by 859
Takayama, T., Sekine, T., Makuuchi, M., Yamasaki, S., Kosuge, T., Yamamoto, J., Shimada, K., Sakamoto, M., Hirohashi, S., Ohashi, Y., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02654-4 · Cited by 847
Budhu, A., Forgues, M., Ye, Q.-H., Jia, H.-L., He, P., Zanetti, K. A., Kammula, U. S., Chen, Y., Qin, L.-X., Tang, Z.-Y., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.06.016 · Cited by 846
Bachem, A., Güttler, S., Hartung, E., Ebstein, F., Schaefer, M., Tannert, A., Salama, A., Movassaghi, K., Opitz, C., Mages, H. W., et al. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20100348 · Cited by 822
Gao, Q., Wang, X.-Y., Qiu, S.-J., Yamato, I., Sho, M., Nakajima, Y., Zhou, J., Li, B.-Z., Shi, Y.-H., Xiao, Y.-S., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1608 · Cited by 813
Stromal Fibroblasts in Cancer: A Novel Tumor-Promoting Cell Type
Orimo, A., & Weinberg, R. A. (2006) · Cell Cycle · doi:10.4161/cc.5.15.3112 · Cited by 799
Hoechst, B., Ormandy, L. A., Ballmaier, M., Lehner, F., Krüger, C., Manns, M. P., Greten, T. F., & Korangy, F. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.03.020 · Cited by 793
Heo, J., Reid, T., Ruo, L., Breitbach, C. J., Rose, S., Bloomston, M., Cho, M., Lim, H. Y., Chung, H. C., Kim, C. W., et al. (2013) · Nature Medicine · doi:10.1038/nm.3089 · Cited by 779
Li, H., Han, Y., Guo, Q., Zhang, M., & Cao, X. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.182.1.240 · Cited by 777
Role of the Microenvironment in the Pathogenesis and Treatment of Hepatocellular Carcinoma
Hernandez–Gea, V., Toffanin, S., Friedman, S. L., & Llovet, J. M. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.01.002 · Cited by 722
Qian, B., Deng, Y., Im, J. H., Muschel, R. J., Zou, Y., Li, J., Lang, R. A., & Pollard, J. W. (2009) · PLoS ONE · doi:10.1371/journal.pone.0006562 · Cited by 664
Sangro, B., Carpanese, L., Cianni, R., Golfieri, R., Gasparini, D., Ezziddin, S., Paprottka, P. M., Fiore, F., Van Buskirk, M., Bilbao, J. I., et al. (2011) · Hepatology · doi:10.1002/hep.24451 · Cited by 652
Self-citationClinical blockade of PD1 and LAG3 — potential mechanisms of action
Nguyen, L. T., & Ohashi, P. S. (2015) · Nature Reviews Immunology · doi:10.1038/nri3790 · Cited by 627
Ostrand-Rosenberg, S., Sinha, P., Beury, D. W., & Clements, V. K. (2012) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2012.01.011 · Cited by 583
Le, D. T., Lutz, E., Uram, J. N., Sugar, E. A., Onners, B., Solt, S., Zheng, L., Diaz, L. A., Donehower, R. C., Jaffee, E. M., et al. (2013) · Journal of Immunotherapy · doi:10.1097/cji.0b013e31829fb7a2 · Cited by 564
Plasma Biomarkers as Predictors of Outcome in Patients with Advanced Hepatocellular Carcinoma
Llovet, J. M., Peña, C. E. A., Lathia, C. D., Shan, M., Meinhardt, G., & Bruix, J. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2175 · Cited by 559
Grosso, J. F., Kelleher, C. C., Harris, T. J., Maris, C. H., Hipkiss, E. L., De Marzo, A., Anders, R., Netto, G., Getnet, D., Bruno, T. C., et al. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31184 · Cited by 547
Kouo, T., Huang, L., Pucsek, A. B., Cao, M., Solt, S., Armstrong, T., & Jaffee, E. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0150 · Cited by 531
Till, B. G., Jensen, M. C., Wang, J., Qian, X., Gopal, A. K., Maloney, D. G., Lindgren, C. G., Lin, Y., Pagel, J. M., Budde, L. E., et al. (2012) · Blood · doi:10.1182/blood-2011-10-387969 · Cited by 529
Park, B.-H., Hwang, T., Liu, T.-C., Sze, D. Y., Kim, J.-S., Kwon, H.-C., Oh, S. Y., Han, S.-Y., Yoon, J.-H., Hong, S.-H., et al. (2008) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70107-4 · Cited by 521
Improved Endpoints for Cancer Immunotherapy Trials
Hoos, A., Eggermont, A. M. M., Janetzki, S., Hodi, F. S., Ibrahim, R., Anderson, A., Humphrey, R., Blumenstein, B., Old, L., & Wolchok, J. (2010) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djq310 · Cited by 518
Zarek, P. E., Huang, C.-T., Lutz, E. R., Kowalski, J., Horton, M. R., Linden, J., Drake, C. G., & Powell, J. D. (2008) · Blood · doi:10.1182/blood-2007-03-081646 · Cited by 515
Li, H., Wu, K., Tao, K., Chen, L., Zheng, Q., Lu, X., Liu, J., Shi, L., Liu, C., Wang, G., et al. (2012) · Hepatology · doi:10.1002/hep.25777 · Cited by 496
Effect of NKG2D ligand expression on host immune responses
Champsaur, M., & Lanier, L. L. (2010) · Immunological Reviews · doi:10.1111/j.0105-2896.2010.00893.x · Cited by 488
Said, E. A., Dupuy, F. P., Trautmann, L., Zhang, Y., Shi, Y., El-Far, M., Hill, B. J., Noto, A., Ancuta, P., Peretz, Y., et al. (2010) · Nature Medicine · doi:10.1038/nm.2106 · Cited by 481
Shi, F., Shi, M., Zeng, Z., Qi, R., Liu, Z., Zhang, J., Yang, Y., Tien, P., & Wang, F. (2011) · International Journal of Cancer · doi:10.1002/ijc.25397 · Cited by 464
Besser, M. J., Shapira-Frommer, R., Treves, A. J., Zippel, D., Itzhaki, O., Hershkovitz, L., Levy, D., Kubi, A., Hovav, E., Chermoshniuk, N., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0041 · Cited by 462
Targeting CD73 Enhances the Antitumor Activity of Anti-PD-1 and Anti-CTLA-4 mAbs
Allard, B., Pommey, S., Smyth, M. J., & Stagg, J. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0545 · Cited by 458
Beatty, G. L., Torigian, D. A., Chiorean, E. G., Saboury, B., Brothers, A., Alavi, A., Troxel, A. B., Sun, W., Teitelbaum, U. R., Vonderheide, R. H., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1320 · Cited by 456
Glypicans: proteoglycans with a surprise
Filmus, J., & Selleck, S. B. (2001) · Journal of Clinical Investigation · doi:10.1172/jci13712 · Cited by 441
(1997) · PubMed · Cited by 433
Tim-3 mediates phagocytosis of apoptotic cells and cross-presentation
Nakayama, M., Akiba, H., Takeda, K., Kojima, Y., Hashiguchi, M., Azuma, M., Yagita, H., & Okumura, K. (2009) · Blood · doi:10.1182/blood-2008-10-185884 · Cited by 432
RECIST revisited: A review of validation studies on tumour assessment
Therasse, P., Eisenhauer, E. A., & Verweij, J. (2006) · European Journal of Cancer · doi:10.1016/j.ejca.2006.01.026 · Cited by 422
Zaiss, D. M. W., van Loosdregt, J., Gorlani, A., Bekker, C. P. J., Gröne, A., Sibilia, M., van Bergen en Henegouwen, P. M. P., Roovers, R. C., Coffer, P. J., & Sijts, A. J. A. M. (2013) · Immunity · doi:10.1016/j.immuni.2012.09.023 · Cited by 418
Infante, J. R., Matsubayashi, H., Sato, N., Tonascia, J., Klein, A. P., Riall, T. A., Yeo, C., Iacobuzio-Donahue, C., & Goggins, M. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.8824 · Cited by 406
Clinicopathological study on hepatocellular carcinoma with lymphocytic infiltration
Wada, Y., Nakashima, O., Kutami, R., Yamamoto, O., & Kojiro, M. (1998) · Hepatology · doi:10.1002/hep.510270214 · Cited by 405
Fernando, R. I., Castillo, M. D., Litzinger, M., Hamilton, D. H., & Palena, C. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0156 · Cited by 400
Fourcade, J., Sun, Z., Pagliano, O., Guillaume, P., Luescher, I. F., Sander, C., Kirkwood, J. M., Olive, D., Kuchroo, V., & Zarour, H. M. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-2637 · Cited by 372
Flecken, T., Schmidt, N., Hild, S., Gostick, E., Drognitz, O., Zeiser, R., Schemmer, P., Bruns, H., Eiermann, T., Price, D. A., et al. (2014) · Hepatology · doi:10.1002/hep.26731 · Cited by 351
Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies
Philips, G. K., & Atkins, M. (2015) · International Immunology · doi:10.1093/intimm/dxu095 · Cited by 335
Hepatocellular carcinoma-associated fibroblasts trigger NK cell dysfunction via PGE2 and IDO
Li, T., Yang, Y., Hua, X., Wang, G., Liu, W., Jia, C., Tai, Y., Zhang, Q., & Chen, G. (2012) · Cancer Letters · doi:10.1016/j.canlet.2011.12.020 · Cited by 328
Creating immune privilege: active local suppression that benefits friends, but protects foes
Mellor, A. L., & Munn, D. H. (2008) · Nature Reviews Immunology · doi:10.1038/nri2233 · Cited by 327
Coughlin, C. M., Salhany, K. E., Gee, M. S., LaTemple, D. C., Kotenko, S., Ma, X., Gri, G., Wysocka, M., Kim, J. E., Liu, L., et al. (1998) · Immunity · doi:10.1016/s1074-7613(00)80585-3 · Cited by 324
Sangro, B., Mazzolini, G., Ruiz, J., Herraiz, M., Quiroga, J., Herrero, I., Benito, A., Larrache, J., Pueyo, J., Subtil, J. C., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.04.059 · Cited by 320
Self-citationTim-3 fosters HCC development by enhancing TGF-β-mediated alternative activation of macrophages
Yan, W., Liu, X., Ma, H., Zhang, H., Song, X., Gao, L., Liang, X., & Ma, C. (2015) · Gut · doi:10.1136/gutjnl-2014-307671 · Cited by 306
Sawada, Y., Yoshikawa, T., Nobuoka, D., Shirakawa, H., Kuronuma, T., Motomura, Y., Mizuno, S., Ishii, H., Nakachi, K., Konishi, M., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-3044 · Cited by 302
Hipp, M. M., Hilf, N., Walter, S., Werth, D., Brauer, K. M., Radsak, M. P., Weinschenk, T., Singh-Jasuja, H., & Brossart, P. (2008) · Blood · doi:10.1182/blood-2007-02-075945 · Cited by 288
Palmer, D. H., Midgley, R. S., Mirza, N., Torr, E. E., Ahmed, F., Steele, J. C., Steven, N. M., Kerr, D. J., Young, L. S., & Adams, D. H. (2009) · Hepatology · doi:10.1002/hep.22626 · Cited by 286
Therapeutic Cancer Vaccines: Current Status and Moving Forward
Schlom, J. (2012) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djs033 · Cited by 282
Wada, J., Ota, K., Kumar, A., Wallner, E. I., & Kanwar, Y. S. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119429 · Cited by 280
CTLA-4 and PD-L1 Checkpoint Blockade Enhances Oncolytic Measles Virus Therapy
Engeland, C. E., Grossardt, C., Veinalde, R., Bossow, S., Lutz, D., Kaufmann, J. K., Shevchenko, I., Umansky, V., Nettelbeck, D. M., Weichert, W., et al. (2014) · Molecular Therapy · doi:10.1038/mt.2014.160 · Cited by 280
Shifting the equilibrium in cancer immunoediting: from tumor tolerance to eradication
Quezada, S. A., Peggs, K. S., Simpson, T. R., & Allison, J. P. (2011) · Immunological Reviews · doi:10.1111/j.1600-065x.2011.01007.x · Cited by 276
Randomized controlled trial of interferon treatment for advanced hepatocellular carcinoma
Llovet, J. M., Sala, M., Castells, L., Suarez, Y., Vilana, R., Bianchi, L., Ayuso, C., Vargas, V., Rodés, J., & Bruix, J. (2000) · Hepatology · doi:10.1002/hep.510310111 · Cited by 271
Zerbini, A., Pilli, M., Penna, A., Pelosi, G., Schianchi, C., Molinari, A., Schivazappa, S., Zibera, C., Fagnoni, F. F., Ferrari, C., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2244 · Cited by 264
CD73 has distinct roles in nonhematopoietic and hematopoietic cells to promote tumor growth in mice
Wang, L., Fan, J., Thompson, L. F., Zhang, Y., Shin, T., Curiel, T. J., & Zhang, B. (2011) · Journal of Clinical Investigation · doi:10.1172/jci45559 · Cited by 262
Unitt, E., Marshall, A., Gelson, W., Rushbrook, S. M., Davies, S., Vowler, S. L., Morris, L. S., Coleman, N., & Alexander, G. J. M. (2006) · Journal of Hepatology · doi:10.1016/j.jhep.2005.12.027 · Cited by 257
Zhou, J., Ding, T., Pan, W., Zhu, L., Li, L., & Zheng, L. (2009) · International Journal of Cancer · doi:10.1002/ijc.24556 · Cited by 256
Arihara, F., Mizukoshi, E., Kitahara, M., Takata, Y., Arai, K., Yamashita, T., Nakamoto, Y., & Kaneko, S. (2013) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-013-1447-1 · Cited by 252
Krempski, J., Karyampudi, L., Behrens, M. D., Erskine, C. L., Hartmann, L., Dong, H., Goode, E. L., Kalli, K. R., & Knutson, K. L. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1100274 · Cited by 251
Prognosis of untreated hepatocellular carcinoma
Giannini, E. G., Farinati, F., Ciccarese, F., Pecorelli, A., Rapaccini, G. L., Di Marco, M., Benvegnù, L., Caturelli, E., Zoli, M., Borzio, F., et al. (2015) · Hepatology · doi:10.1002/hep.27443 · Cited by 250
Immune checkpoint blockade in hepatocellular carcinoma: Current progress and future directions
Hato, T., Goyal, L., Greten, T. F., Duda, D. G., & Zhu, A. X. (2014) · Hepatology · doi:10.1002/hep.27246 · Cited by 241
TGF-β-dependent induction of CD4+CD25+Foxp3+ Tregs by liver sinusoidal endothelial cells
Carambia, A., Freund, B., Schwinge, D., Heine, M., Laschtowitz, A., Huber, S., Wraith, D. C., Korn, T., Schramm, C., Lohse, A. W., et al. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2014.04.027 · Cited by 241
Chen, K.-J., Lin, S.-Z., Zhou, L., Xie, H.-Y., Zhou, W.-H., Taki-Eldin, A., & Zheng, S.-S. (2011) · PLoS ONE · doi:10.1371/journal.pone.0024671 · Cited by 240
Butterfield, L. H., Ribas, A., Dissette, V. B., Lee, Y., Yang, J. Q., De la Rocha, P., Duran, S. D., Hernandez, J., Seja, E., Potter, D. M., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2856 · Cited by 232
Montesinos, M. C., Desai, A., Chen, J.-F., Yee, H., Schwarzschild, M. A., Fink, J. S., & Cronstein, B. N. (2002) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)61151-0 · Cited by 231
Enhanced suppressor function of TIM‐3+FoxP3+ regulatory T cells
Gautron, A., Dominguez‐Villar, M., de Marcken, M., & Hafler, D. A. (2014) · European Journal of Immunology · doi:10.1002/eji.201344392 · Cited by 228
Han, Y., Chen, Z., Yang, Y., Jiang, Z., Gu, Y., Liu, Y., Lin, C., Pan, Z., Yu, Y., Jiang, M., et al. (2014) · Hepatology · doi:10.1002/hep.26694 · Cited by 226
Multistep human hepatocarcinogenesis: correlation of imaging with pathology
Kudo, M. (2009) · Journal of Gastroenterology · doi:10.1007/s00535-008-2274-6 · Cited by 224
Adenosine receptors and cancer
Gessi, S., Merighi, S., Sacchetto, V., Simioni, C., & Borea, P. A. (2011) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2010.09.020 · Cited by 224
Jinushi, M., Takehara, T., Tatsumi, T., Hiramatsu, N., Sakamori, R., Yamaguchi, S., & Hayashi, N. (2005) · Journal of Hepatology · doi:10.1016/j.jhep.2005.05.026 · Cited by 220
Chen, Y., Huang, Y., Reiberger, T., Duyverman, A. M., Huang, P., Samuel, R., Hiddingh, L., Roberge, S., Koppel, C., Lauwers, G. Y., et al. (2014) · Hepatology · doi:10.1002/hep.26790 · Cited by 211
Greten, T. F., Forner, A., Korangy, F., N'Kontchou, G., Barget, N., Ayuso, C., Ormandy, L. A., Manns, M. P., Beaugrand, M., & Bruix, J. (2010) · BMC Cancer · doi:10.1186/1471-2407-10-209 · Cited by 208
El-Khoueiry, A. B., Melero, I., Crocenzi, T. S., Welling, T. H., Yau, T. C., Yeo, W., Chopra, A., Grosso, J., Lang, L., Anderson, J., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.18_suppl.lba101 · Cited by 195
Self-citationZhu, A. X., Gold, P. J., El-Khoueiry, A. B., Abrams, T. A., Morikawa, H., Ohishi, N., Ohtomo, T., & Philip, P. A. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2616 · Cited by 193
Yoong, K. F., McNab, G., Hübscher, S. G., & Adams, D. H. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.160.8.3978 · Cited by 190
Exploiting CTLA-4, PD-1 and PD-L1 to reactivate the host immune response against cancer
Quezada, S. A., & Peggs, K. S. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.117 · Cited by 190
Chi, K.-H., Liu, S.-J., Li, C.-P., Kuo, H.-P., Wang, Y.-S., Chao, Y., & Hsieh, S.-L. (2005) · Journal of Immunotherapy · doi:10.1097/01.cji.0000154248.74383.5e · Cited by 187
Lee, W.-C., Wang, H.-C., Hung, C.-F., Huang, P.-F., Lia, C.-R., & Chen, M.-F. (2005) · Journal of Immunotherapy · doi:10.1097/01.cji.0000171291.72039.e2 · Cited by 185
Mazzolini, G., Alfaro, C., Sangro, B., Feijoó, E., Ruiz, J., Benito, A., Tirapu, I., Arina, A., Sola, J., Herraiz, M., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.00.463 · Cited by 179
Self-citationAgonist Antibodies to TNFR Molecules That Costimulate T and NK Cells
Melero, I., Hirschhorn-Cymerman, D., Morales-Kastresana, A., Sanmamed, M. F., & Wolchok, J. D. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2065 · Cited by 176
Self-citationKawaguchi, Y., Kono, K., Mimura, K., Sugai, H., Akaike, H., & Fujii, H. (2007) · International Journal of Cancer · doi:10.1002/ijc.22370 · Cited by 174
Preliminary data from a multi-arm expansion study of MEDI4736, an anti-PD-L1 antibody.
Segal, N. H., Antonia, S. J., Brahmer, J. R., Maio, M., Blake-Haskins, A., Li, X., Vasselli, J., Ibrahim, R. A., Lutzky, J., & Khleif, S. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.15_suppl.3002 · Cited by 173
Design and implementation of adoptive therapy with chimeric antigen receptor‐modified T cells
Jensen, M. C., & Riddell, S. R. (2013) · Immunological Reviews · doi:10.1111/imr.12139 · Cited by 170
Expression and prognosis role of indoleamine 2,3-dioxygenase in hepatocellular carcinoma
Pan, K., Wang, H., Chen, M.-S., Zhang, H.-K., Weng, D.-S., Zhou, J., Huang, W., Li, J.-J., Song, H.-F., & Xia, J.-C. (2008) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-008-0395-1 · Cited by 169
Sprinzl, M. F., Reisinger, F., Puschnik, A., Ringelhan, M., Ackermann, K., Hartmann, D., Schiemann, M., Weinmann, A., Galle, P. R., Schuchmann, M., et al. (2013) · Hepatology · doi:10.1002/hep.26328 · Cited by 169
Neaud, V, Faouzi, S., Guirouilh, J., Le Bail, B., Balabaud, C., Bioulac-Sage, P., & Rosenbaum, J. (1997) · Hepatology · doi:10.1002/hep.510260612 · Cited by 167
Moo-Young, T. A., Larson, J. W., Belt, B. A., Tan, M. C., Hawkins, W. G., Eberlein, T. J., Goedegebuure, P. S., & Linehan, D. C. (2009) · Journal of Immunotherapy · doi:10.1097/cji.0b013e318189f13c · Cited by 165
Karyampudi, L., Lamichhane, P., Scheid, A. D., Kalli, K. R., Shreeder, B., Krempski, J. W., Behrens, M. D., & Knutson, K. L. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-2564 · Cited by 162
Zhao, Q., Kuang, D.-M., Wu, Y., Xiao, X., Li, X.-F., Li, T.-J., & Zheng, L. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1100164 · Cited by 161
Dunham, R. M., Thapa, M., Velazquez, V. M., Elrod, E. J., Denning, T. L., Pulendran, B., & Grakoui, A. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1201937 · Cited by 161
Dendritic Cells as Pharmacological Tools for Cancer Immunotherapy
Anguille, S., Smits, E., Bryant, C. E., Acker, H. H. V., Goossens, H., Lion, E., Fromm, P. D., Hart, D. N. J., Tendeloo, V. F. V., & Berneman, Z. N. (2015) · Pharmacological Reviews · doi:10.1124/pr.114.009456 · Cited by 161
Hirschhorn-Cymerman, D., Budhu, S., Kitano, S., Liu, C., Zhao, F., Zhong, H., Lesokhin, A. M., Avogadri-Connors, F., Yuan, J., Li, Y., et al. (2012) · Journal of Experimental Medicine · doi:10.1084/jem.20120532 · Cited by 159
Weng, D., Zhou, J., Zhou, Q.-M., Zhao, M. D., Wang, Q.-J., Huang, L.-X., Li, Y.-Q., Chen, S.-P., Wu, P., & Xia, J. (2008) · Journal of Immunotherapy · doi:10.1097/cji.0b013e31815a121b · Cited by 155
Perugorria, M. J., Latasa, M. U., Nicou, A., Cartagena‐Lirola, H., Castillo, J., Goñi, S., Vespasiani‐Gentilucci, U., Zagami, M. G., Lotersztajn, S., Prieto, J., et al. (2008) · Hepatology · doi:10.1002/hep.22437 · Cited by 151
Hui, D., Li, Q., Jian, W., Zhang, T., & Kong, D. (2008) · Digestive and Liver Disease · doi:10.1016/j.dld.2008.04.007 · Cited by 151
Kohga, K., Takehara, T., Tatsumi, T., Ishida, H., Miyagi, T., Hosui, A., & Hayashi, N. (2009) · Hepatology · doi:10.1002/hep.23456 · Cited by 149
Höchst, B., Schildberg, F. A., Sauerborn, P., Gäbel, Y. A., Gevensleben, H., Goltz, D., Heukamp, L. C., Türler, A., Ballmaier, M., Gieseke, F., et al. (2013) · Journal of Hepatology · doi:10.1016/j.jhep.2013.04.033 · Cited by 147
Desar, I. M. E., Jacobs, J. F. M., Hulsbergen‐vandeKaa, C. A., Oyen, W. J. G., Mulders, P., van der Graaf, W. T. A., Adema, G. J., van Herpen, C. M. L., & de Vries, I. J. M. (2010) · International Journal of Cancer · doi:10.1002/ijc.25674 · Cited by 146
Role of the microenvironment in hepatocellular carcinoma development and progression
Wu, S., Ma, Y., Fang, Y., Liu, L., Fu, D., & Shen, X. (2011) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2011.06.010 · Cited by 145
Hernandez-Chacon, J. A., Li, Y., Wu, R. C. H., Bernatchez, C., Wang, Y., Weber, J. S., Hwu, P., & Radvanyi, L. G. (2011) · Journal of Immunotherapy · doi:10.1097/cji.0b013e318209e7ec · Cited by 141
Cedeno‐Laurent, F., Opperman, M. J., Barthel, S. R., Kuchroo, V. K., & Dimitroff, C. J. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1103433 · Cited by 140
Chen, L., Chen, M., Li, L.-A., Lee, P., Jeng, L., Lin, D., Wu, C.-C., Mok, K., Chen, C., Lee, W., et al. (2011) · Annals of Surgery · doi:10.1097/sla.0b013e3182363ff9 · Cited by 137
TGF-β and kynurenines as the key to infectious tolerance
Belladonna, M. L., Orabona, C., Grohmann, U., & Puccetti, P. (2009) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2008.11.006 · Cited by 134
Tumor-Associated Galectin-3 Modulates the Function of Tumor-Reactive T Cells
Peng, W., Wang, H. Y., Miyahara, Y., Peng, G., & Wang, R. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1245 · Cited by 128
Biomarkers on melanoma patient T Cells associated with ipilimumab treatment
Wang, W., Yu, D., Sarnaik, A. A., Yu, B., Hall, M. S., Morelli, D., Zhang, Y., Zhao, X., & Weber, J. S. (2012) · Journal of Translational Medicine · doi:10.1186/1479-5876-10-146 · Cited by 126
Impact of tumour microenvironment and Fc receptors on the activity of immunomodulatory antibodies
Furness, A. J. S., Vargas, F. A., Peggs, K. S., & Quezada, S. A. (2014) · Trends in Immunology · doi:10.1016/j.it.2014.05.002 · Cited by 125
Reduced NKG2D ligand expression in hepatocellular carcinoma correlates with early recurrence
Kamimura, H., Yamagiwa, S., Tsuchiya, A., Takamura, M., Matsuda, Y., Ohkoshi, S., Inoue, M., Wakai, T., Shirai, Y., Nomoto, M., et al. (2011) · Journal of Hepatology · doi:10.1016/j.jhep.2011.06.017 · Cited by 124
Dendritic cells and cancer immunotherapy
Radford, K. J., Tullett, K. M., & Lahoud, M. H. (2014) · Current Opinion in Immunology · doi:10.1016/j.coi.2014.01.005 · Cited by 121
Glypican‐3 antibodies: A new therapeutic target for liver cancer
Feng, M., & Ho, M. (2013) · FEBS Letters · doi:10.1016/j.febslet.2013.10.002 · Cited by 120
Tada, F., Abe, M., Hirooka, M., Ikeda, Y., Hiasa, Y., Lee, Y., Jung, N.-C., LEE, W.-B., Lee, H., Bae, Y., et al. (2012) · International Journal of Oncology · doi:10.3892/ijo.2012.1626 · Cited by 120
Quetglas, J. I., Labiano, S., Aznar, M. A., Bolaños, E., Azpilikueta, A., Rodríguez, I., Casales, E., Sánchez-Paulete, A. R., Segura, V., Smerdou, C., et al. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0216 · Cited by 116
Self-citationImmunotherapy by autologous dendritic cell vaccine in patients with advanced HCC
Ansary, M. E., Mogawer, S., Elhamid, S. A., Alwakil, S., Aboelkasem, F., Sabaawy, H. E., & Abdelhalim, O. (2012) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-012-1298-8 · Cited by 108
Phan, G. Q., & Rosenberg, S. A. (2013) · Cancer Control · doi:10.1177/107327481302000406 · Cited by 107
Amphiregulin: A new growth factor in hepatocarcinogenesis
Berasain, C., Castillo, J., Perugorria, M. J., Prìeto, J., & Avila, M. A. (2007) · Cancer Letters · doi:10.1016/j.canlet.2007.01.015 · Cited by 99
HLA ligandome tumor antigen discovery for personalized vaccine approach
Rammensee, H., & Singh‐Jasuja, H. (2013) · Expert Review of Vaccines · doi:10.1586/14760584.2013.836911 · Cited by 97
Expression and function of interleukin-8 in human hepatocellular carcinoma
Akiba, J., Yano, H., Ogasawara, S., Higaki, K., & Kojiro, M. (2001) · International Journal of Oncology · doi:10.3892/ijo.18.2.257 · Cited by 93
Sawada, Y., Yoshikawa, T., Shimomura, M., Iwama, T., Endo, I., & Nakatsura, T. (2014) · International Journal of Oncology · doi:10.3892/ijo.2014.2737 · Cited by 91
Yu, X., Zhao, H., Liu, L., Cao, S., Ren, B., Zhang, N., An, X., Yu, J., Li, H., & Ren, X. (2013) · Journal of Clinical Immunology · doi:10.1007/s10875-013-9976-0 · Cited by 85
Castillo, J., Goñi, S., Latasa, M. U., Perugorria, M. J., Calvo, A., Muntané, J., Bioulac‐Sage, P., Balabaud, C. P., Prìeto, J., Avila, M. A., et al. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.07.065 · Cited by 81
Interfering with coinhibitory molecules: BTLA/HVEM as new targets to enhance anti-tumor immunity
Pasero, C., & Olive, D. (2013) · Immunology Letters · doi:10.1016/j.imlet.2013.01.008 · Cited by 76
Pan, K., Li, Y.-Q., Wang, W., Xu, L., Zhang, Y., Zheng, H.-X., Zhao, J.-J., Qiu, H., Weng, D., Li, X. H., et al. (2013) · Annals of Surgical Oncology · doi:10.1245/s10434-013-3144-x · Cited by 75
Tumour‐induced immune suppression: role of inflammatory mediators released by myelomonocytic cells
Mao, Y., Poschke, I. C., & Kiessling, R. W. (2014) · Journal of Internal Medicine · doi:10.1111/joim.12229 · Cited by 74
Zabala, M., Lasarte, J. J., Perret, C., Sola, J., Berraondo, P., Alfaro, M., Larrea, E., Prìeto, J., & Kramer, M. G. (2007) · Journal of Hepatology · doi:10.1016/j.jhep.2007.07.025 · Cited by 73
Galectins and their ligands: negative regulators of anti-tumor immunity
Cedeno‐Laurent, F., & Dimitroff, C. J. (2012) · Glycoconjugate Journal · doi:10.1007/s10719-012-9379-0 · Cited by 65
Immunological off-target effects of standard treatments in gastrointestinal cancers
Duffy, A. G., & Greten, T. F. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt349 · Cited by 63
Clinical impact of herpesvirus entry mediator expression in human hepatocellular carcinoma
Hokuto, D., Sho, M., Yamato, I., Yasuda, S., Obara, S., Nomi, T., & Nakajima, Y. (2014) · European Journal of Cancer · doi:10.1016/j.ejca.2014.11.004 · Cited by 62
Quetglas, J. I., Dubrot, J., Bezunartea, J., Sanmamed, M. F., Hervás‐Stubbs, S., Smerdou, C., & Melero, I. (2012) · Molecular Therapy · doi:10.1038/mt.2012.56 · Cited by 59
Self-citationVirus-induced hepatocellular carcinomas cause antigen-specific local tolerance
Willimsky, G., Schmidt, K., Loddenkemper, C., Gellermann, J., & Blankenstein, T. J. F. (2013) · Journal of Clinical Investigation · doi:10.1172/jci64742 · Cited by 55
Harnessing Human Cross-Presenting CLEC9A+XCR1+ Dendritic Cells for Immunotherapy
Tullett, K. M., Lahoud, M. H., & Radford, K. J. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00239 · Cited by 55
Yan, W., Han, P., Zhou, Z., Tu, W., Liao, J., Li, P., Liu, M., Tian, D., & Fu, Y. (2014) · Digestive Diseases and Sciences · doi:10.1007/s10620-013-3016-z · Cited by 52
Lü, Y., Lin, N., Chen, Z., & Xu, R. (2014) · Molecular Medicine Reports · doi:10.3892/mmr.2014.2689 · Cited by 52
Improving the efficacy and safety of engineered T cell therapy for cancer
Shi, H., Liu, L., & Wang, Z. (2012) · Cancer Letters · doi:10.1016/j.canlet.2012.09.015 · Cited by 48
Immunotherapy for castration-resistant prostate cancer: Progress and new paradigms
Quinn, D. I., Shore, N. D., Egawa, S., Gerritsen, W. R., & Fizazi, K. S. (2015) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2014.10.009 · Cited by 47
Nakamoto, Y., Mizukoshi, E., Tsuji, H., Sakai, Y., Kitahara, M., Kazumori, A. R. A. I., Yamashita, T., Yokoyama, K., Mukaida, N., Matsushima, K., et al. (2007) · Clinical & Experimental Immunology · doi:10.1111/j.1365-2249.2006.03290.x · Cited by 46
Translation of genomics-guided RNA-based personalised cancer vaccines: towards the bedside
Boisguérin, V., Castle, J. C., Löewer, M., Diekmann, J., Mueller, F., Britten, C. M., Kreiter, S., Türeci, Ö., & Şahin, U. (2014) · British Journal of Cancer · doi:10.1038/bjc.2013.820 · Cited by 43
El-Khoueiry, A. B., Melero, I., Crocenzi, T. S., Welling, T. H., Yau, T. C., Yeo, W., Chopra, A., Grosso, J. F., Lang, L., Anderson, J., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.15_suppl.lba101 · Cited by 42
Self-citationImmune Control in Hepatocellular Carcinoma Development and Progression: Role of Stromal Cells
Sprinzl, M. F., & Galle, P. R. (2014) · Seminars in Liver Disease · doi:10.1055/s-0034-1394138 · Cited by 38
Morisaki, T., Hirano, T., Koya, N., Kiyota, A., Tanaka, H., Umebayashi, M., Onishi, H., & Katano, M. (2014) · PubMed · Cited by 34
Zhu, X., Sun, H., Xu, H., Kong, L., Chai, Z., Lu, L., Zhang, J., Gao, D., Wang, W., Zhang, W., et al. (2013) · Angiogenesis · doi:10.1007/s10456-013-9357-6 · Cited by 30
Self-inactivating helper virus for the production of high-capacity adenoviral vectors
González-Aparicio, M., Mauleón, I., Alzuguren, P., Buñuales, M., González‐Aseguinolaza, G., Martín, C. S., Prìeto, J., & Hernández-Alcoceba, R. (2011) · Gene Therapy · doi:10.1038/gt.2011.58 · Cited by 27
Recent advances in oncolytic virus design
Hernández-Alcoceba, R. (2011) · Clinical & Translational Oncology · doi:10.1007/s12094-011-0647-4 · Cited by 25
Gene therapy of liver diseases: A 2011 perspective
González‐Aseguinolaza, G., & Prìeto, J. (2011) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2011.05.016 · Cited by 14
Cytokines for the treatment of gastrointestinal cancers: clinical experience and new perspectives
Hernández-Alcoceba, R., Sangro, B., Berraondo, P., González‐Aseguinolaza, G., & Prìeto, J. (2013) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2013.793307 · Cited by 10
Self-citation
Cited by
Forner, A., Reig, M., & Bruix, J. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30010-2 · Cited by 5,531
El-Khoueiry, A. B., Sangro, B., Yau, T., Crocenzi, T. S., Kudo, M., Hsu, C., Kim, T.-Y., Choo, S.-P., Trojan, J., Welling, T. H., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31046-2 · Cited by 4,280
Self-citationComprehensive and Integrative Genomic Characterization of Hepatocellular Carcinoma
Ally, A., Balasundaram, M., Carlsen, R., Chuah, E., Clarke, A., Dhalla, N., Holt, R. A., Jones, S. J. M., Lee, D., Ma, Y., et al. (2017) · Cell · doi:10.1016/j.cell.2017.05.046 · Cited by 2,490
Zhu, A. X., Finn, R. S., Edeline, J., Cattan, S., Ogasawara, S., Palmer, D., Verslype, C., Zagonel, V., Fartoux, L., Vogel, A., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30351-6 · Cited by 2,479
Landscape of Infiltrating T Cells in Liver Cancer Revealed by Single-Cell Sequencing
Zheng, C., Zheng, L., Yoo, J.-K., Guo, H., Zhang, Y., Guo, X., Kang, B., Hu, R., Huang, J. Y., Zhang, Q., et al. (2017) · Cell · doi:10.1016/j.cell.2017.05.035 · Cited by 2,152
Metadata
- Authors
- Prieto, J., Melero, I., & Sangro, B.
- Venue
- Nature Reviews Gastroenterology & Hepatology
- Published
- 2015-10-20
- Volume
- 12
- Issue
- 12
- Pages
- 681-700
- ISSN
- 1759-5045 (ISSN-L)
- 1759-5053
- OpenAlex
- W2194546364
- Cited by
- 566
- References
- 203
- FWCI
- 6.66
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.